Abstract
Recent advance of molecular biology and immunology contributes to the development biologics such as anti-TNFα agent in the treatment for inflammatory bowel disease (IBD). Although therapeutic strategy of IBD has not been changed for a long time, success of Infliximab, first anti-TNFα agent, now changes therapeutic strategy of IBD dramatically. Top-down strategy has been considered to improve patients' natural history in the therapy for Crohn's disease as well as in rheumatoid arthritis. Infliximab also has been expected as a promising medicine for pediatric Crohn's disease. Furthermore, Infliximab has been approved for the therapy of ulcerative colitis. These tremendous successes of Infliximab have encouraged us to develop other anti-TNF agents and other biologics. In this review, we describe current topics of biologics in IBD treatment and discuss future direction.
| Original language | English |
|---|---|
| Pages (from-to) | 168-179 |
| Number of pages | 12 |
| Journal | Japanese Journal of Clinical Immunology |
| Volume | 32 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2009 |
Keywords
- Biologics
- Inflammatory bowel disease
- TNFα
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology